Abstract P195: Omacetaxine mepessucinate plus venetoclax show strong synergistic anti-leukemic activity in nucleophosmin (NPM1)-mutated AML patient-derived xenograft (PDX) models to support a phase 1 clinical trial

2021 ◽  
Author(s):  
Federica Mezzasoma ◽  
Valeria Cardinali ◽  
Ilaria Gionfriddo ◽  
Francesca Milano ◽  
Sofia Sciabolacci ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase 1 ◽  
Phase 1 Clinical Trial ◽  
Patient Derived Xenograft ◽  
Pdx Models

A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome

Vaccine ◽  
2012 ◽  
Vol 30 (11) ◽  
pp. 1951-1958 ◽  
Author(s):  
Ellen F. Boudreau ◽  
Matthew Josleyn ◽  
Diane Ullman ◽  
Diana Fisher ◽  
Lonnie Dalrymple ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dna Vaccines ◽  
Phase 1 ◽  
Hemorrhagic Fever ◽  
Hantaan Virus ◽  
Puumala Virus ◽  
Phase 1 Clinical Trial

scholarly journals A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2308-2316 ◽  
Author(s):  
David H. McDermott ◽  
Qian Liu ◽  
Daniel Velez ◽  
Lizbeeth Lopez ◽  
Sandra Anaya-O’Brien ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Low Dose ◽  
Phase 1 ◽  
Cxcr4 Antagonist ◽  
Phase 1 Clinical Trial ◽  
Dose Treatment ◽  
Whim Syndrome ◽  
Key Points

Key Points Plerixafor can be given safely to WHIM syndrome patients twice daily for a 6-month period and appears promising as a treatment.

Sign in / Sign up

Export Citation Format

Share Document